Cargando…

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer

OBJECTIVE: There is no research regarding the appropriate antiemetic agents for female patients, especially those receiving moderately emetogenic chemotherapy (MEC). We evaluated the antiemetic efficacy of a combination of 5-HT(3) receptor with/without aprepitant in patients with gynecological cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Satoe, Terai, Yoshito, Tsunetoh, Satoshi, Sasaki, Hiroshi, Kanemura, Masanori, Ohmichi, Masahide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620368/ https://www.ncbi.nlm.nih.gov/pubmed/26197776 http://dx.doi.org/10.3802/jgo.2015.26.4.311

Ejemplares similares

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - A comparative evaluation
por: Gupta, Kumkum, et al.
Publicado: (2014)

Palonosetron and granisetron in postoperative nausea vomiting: A randomized double-blind prospective study
por: Gugale, Amrita A., et al.
Publicado: (2016)

Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial
por: Lee, Won-Suk, et al.
Publicado: (2015)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
por: Wakasugi, Yoshinori, et al.
Publicado: (2019)

Comparison of Palonosetron with Granisetron for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Abdominal Surgery
por: Tahir, Sifna, et al.
Publicado: (2018)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
por: Yoshida, Naohisa, et al.
Publicado: (2019)

A Comparative Study Between Palonosetron and Granisetron to Prevent Postoperative Nausea and Vomiting after Laparoscopic Cholecystectomy
por: Bhattacharjee, Dhurjoti Prosad, et al.
Publicado: (2010)

Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study
por: MATSUDA, Masahide, et al.
Publicado: (2016)

Neoadjuvant intra-arterial chemotherapy using an original four-lumen double-balloon catheter for locally advanced uterine cervical cancer
por: Tanaka, Tomohito, et al.
Publicado: (2018)

Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer
por: Tanaka, Yoshimichi, et al.
Publicado: (2013)

Mucinous adenocarcinoma of the intestinal type arising from mature cystic teratoma of the ovary: a rare case report and review of the literature
por: Takai, Masaaki, et al.
Publicado: (2012)

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting
por: Uchida, Mayako, et al.
Publicado: (2018)

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Schwartzberg, Lee, et al.
Publicado: (2013)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
por: Yoo, Jae Hwa, et al.
Publicado: (2018)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
por: Cheng, Yi, et al.
Publicado: (2022)

The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer
por: Takai, Masaaki, et al.
Publicado: (2014)

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
por: Kawaguchi, Hiroshi, et al.
Publicado: (2014)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer
por: Fujiwara, Satoe, et al.
Publicado: (2012)

CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer
por: TANAKA, TOMOHITO, et al.
Publicado: (2015)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

The detection of sentinel lymph nodes in laparoscopic surgery can eliminate systemic lymphadenectomy for patients with early stage endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial
por: Moon, Hyoung Yong, et al.
Publicado: (2014)

Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial
por: Grigio, Thiago Ramos, et al.
Publicado: (2020)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Management of postoperative nausea and vomiting: focus on palonosetron
por: Muchatuta, Neil A, et al.
Publicado: (2009)

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy
por: Toda, Haruka, et al.
Publicado: (2017)

Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
por: Tsunetoh, Satoshi, et al.
Publicado: (2019)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
por: Shimizu, Hisanori, et al.
Publicado: (2018)

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.
por: Aapro, M. S., et al.
Publicado: (1994)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cj32oif6rl081606prpkkbgjbo